2nd European Lung Cancer Conference

2nd European Lung Cancer Conference

28 April - 01 May, 2010
Geneva, Switzerland

  1. Opening session
  2. Tobacco control
  3. Stage IIIA N2 NSCLC
  4. Implications of the new staging system – case-based
  5. The emerging role of immunotherapy in lung cancer
  6. Restaging techniques
  7. The management of pleural effusion
  8. Chemotherapy for the elderly
  9. Thymomas
  10. Improving survival in LS-SCLC and ES-SCLC with radiotherapy
  11. Circulating lung cancer cells
  12. Early NSCLC stage I/II: State-of-the-art
  13. Early NSCLC invited papers
  14. Pathology, biology and translational research
  15. Supportive and palliative care
  16. Molecular biology
  17. Early NSCLC controversial issues
  18. Radiation
  19. Early NSCLC
  20. Biology
  21. The new ERS/IASLC/ATS classification of lung adenocarcinoma
  22. Imaging: State-of-the-art
  23. Mesothelioma
  24. Screening
  25. SCLC: Drugs and targeted therapies
  26. The management of brain metastases
  27. The new frontiers in surgery in T4 tumors and metastatic disease
  28. Stage III NSCLC: State-of-the-art
  29. Stage III NSCLC invited papers
  30. Translational research
  31. Metastatic NSCLC: State-of-the-art
  32. Combined modality therapy
  33. Metastatic NSCLC, biology from the benchmark to bedside invited papers
  34. Technical aspects of radiotherapy
  35. Surgery
  36. Advanced NSCLC
  37. Imaging
  38. Mesothelioma and SCLC
  39. Safety and toxicity
  40. Prevention, locally advanced and early NSCLC
  41. Advanced NSCLC
  42. Translational research and biology
  43. Future directions in the treatment of NSCLC
  44. Controversy session - stage III: Combined treatment
  45. Controversy session - stage IV: targeted therapy as first line treatment
  46. Grand round

Search within Webcasts

 
 

 

 
 
 
 
 
 

Most Viewed Webcasts